# Viscient Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viscient-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.viscientbiosciences.com
- Latest round: Series A (Jun 10, 2019)
- Investors on record: 2

## About

Viscient Bio Inc. is a biotechnology firm that innovates in advanced 3D tissue technology, creating human tissue models for drug development, primarily targeting pharmaceutical companies and research institutions.Founded in 2017 and headquartered in San Diego, US, Viscient Bio Inc. focuses on developing sophisticated human tissue models, including a liver model that accurately mimics fatty liver disease. The company was co-founded by Jeffrey Miner and Keith Murphy, with Keith Murphy serving as CEO. Viscient Bio has engaged in 2 deals, with the most recent funding round occurring on June 10, 2019.Viscient Biosciences specializes in advanced biotechnology, particularly through its innovative 3D tissue technology. The company’s core product offerings include sophisticated human tissue models, specifically its liver model, which has garnered recognition for accurately representing the characteristics of fatty liver disease. These models are designed to replace traditional animal testing, providing more relevant data for drug development while showcasing known disease patterns through microscopy and gene expression analysis. The primary end users of these products are pharmaceutical companies and research institutions engaged in drug development and safety testing. Viscient’s products are positioned in global markets, particularly targeting North America and Europe, where there is a growing demand for ethical and effective alternatives to animal models in biomedical research.Viscient Biosciences generates revenue through business-to-business transactions with pharmaceutical and biotechnology companies, leveraging their proprietary 3D tissue models in drug development processes. The structure of transactions typically involves partnerships and collaborations, where clients may engage Viscient to utilize their liver model in preclinical studies. Revenue is expected to derive from service agreements and licensing arrangements related to drug candidates developed using Viscient’s technology. The company is actively advancing its drug development pipeline, with one drug already progressing to the preclinical stage and another set for Phase 2 studies, indicating a strategic focus on monetizing its technology through successful drug outcomes and associated collaborations. This approach not only secures direct revenue streams but also establishes Viscient's models as essential tools in the evolving landscape of pharmaceutical development.In June 2019, Viscient Bio Inc. raised an undisclosed amount in Series A funding from Methuselah Fund and Thynk Capital. The company plans to utilize this funding to enhance its product offerings and expand its market presence, particularly in North America and Europe. It aims to launch new 3D tissue models in the coming years, improving the capabilities of its existing liver model and potentially introducing new models tailored to different disease states. Viscient is also looking to establish collaborations with additional pharmaceutical companies to broaden its reach and impact in drug development, indicating a strategic growth trajectory focused on innovation and market expansion.

## Funding rounds

- Series A, Jun 10, 2019 — Thynk Capital, Methuselah Fund
- Seed, May 30, 2019 — Thynk Capital

## Investors

- Thynk Capital (https://capitalatlas.ai/funds/thynk-capital) — Seed, Series A
- Methuselah Fund (https://capitalatlas.ai/funds/methuselah-fund) — Series A